PALO ALTO, Calif., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the interview with Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group, will be broadcast on Wide World of Stocks today, Thursday, January 15, at 5:00 p.m. and 6:00 p.m. EST into more than 50 million homes nationwide over BizTV, BizTV Radio, and Youtoo America Networks.
In the interview, Dr. Cao provides insight into the company's recent successes from its Phase I/IIa clinical trial for Rejoin™ human adipose-derived mesenchymal progenitor cell (haMPC) regenerative therapy for Knee Osteoarthritis (KOA), and other clinical progress, as well as strengthening the Company's already impressive IP portfolio, including the build-out of its immune cell therapy platform focused on oncology. "It was a pleasure to present Cellular Biomedicine Group's compelling value proposition. We are looking forward to continued progress in our clinical trials and communicating this information to our shareholders and partners," said Dr. Cao.
WWOS' interview with Cellular Biomedicine Group can be seen nationwide today on BizTv at 5:00pm EST and on Youtoo America (formally America One Network) at 6:00pm EST.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
About Wide World of Stocks
Wide World of Stocks delivers visibility to companies in the small-cap sector. Wide World of Stocks offers a complete multi-level awareness package that provides valuable exposure for your company, products and services. Wide World of Stocks is a print and digital content provider with multi-channel integration including television, webcasts, podcasts and a magazine in both digital and print formats. WWOS has been seen in 100+ million homes, regionally and nationally on cable and major networks including CBS, NBC, ABC, and FOX. For more information visit www.wideworldofstocks.com. Wide World of Stocks is owned and published by Valhalla Venture Group, LLC. Learn more at www.wideworldofstocks.com.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 email@example.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 firstname.lastname@example.org
Source:Cellular Biomedicine Group Inc.